Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
- Hyman B. Muss, MD;
- Susan Woolf, BS;
- Donald Berry, PhD;
- Constance Cirrincione, MS;
- Raymond B. Weiss, MD;
- Daniel Budman, MD;
- William C. Wood, MD;
- I. Craig Henderson, MD;
- Clifford Hudis, MD;
- Eric Winer, MD;
- Harvey Cohen, MD;
- Judith Wheeler, BA, MPH;
- Larry Norton, MD;
- for the Cancer and Leukemia Group B
- Author Affiliations: Vermont Cancer Center, Burlington (Dr Muss); Cancer and Leukemia Group B Statistical Center (Mss Woolf, Cirrincione, and Wheeler) and Duke University and Veterans Administration Medical Centers (Dr Cohen), Durham, NC; M. D. Anderson Cancer Center, Houston, Tex (Dr Berry); Georgetown University Medical Center, Washington, DC (Dr Weiss); North Shore University Hospital–New York University, Manhasset, NY (Dr Budman); Massachusetts General Hospital (Dr Wood) and Dana Farber Cancer Institute (Dr Winer), Boston; Emory University School of Medicine, Atlanta, Ga (Dr Wood); University of California, San Francisco (Dr Henderson); and Memorial Sloan-Kettering Cancer Center, New York, NY (Drs Hudis and Norton).
- Corresponding Author: Hyman B. Muss, MD, Fletcher Allen Health Care, Vermont Cancer Center, UHC Campus, St Joseph 3400, 1 S Prospect St, Burlington, VT 05401 (hyman.muss{at}uvm.edu).
Abstract
Context Adjuvant chemotherapy improves survival for patients with local-regional breast cancer, but healthy older patients at high risk of recurrence are frequently not offered adjuvant chemotherapy, and the benefit of adjuvant chemotherapy in older patients is uncertain.
Objective To compare the benefits and toxic effects of adjuvant chemotherapy among breast cancer patients in age groups of 50 years or younger, 51 to 64 years, and 65 years or older.
Design and Setting Retrospective review of data from 4 randomized trials that accrued patients from academic and community medical centers between 1975 and 1999. Median follow-up for all patients was 9.6 years. All trials randomized patients to different regimens, doses, schedules, and durations of chemotherapy and all had a treatment arm with doses or schedules that were regarded to be “high” and potentially more toxic.
Patients A total of 6487 women with lymph node–positive breast cancer; 542 (8%) patients were 65 years or older and 159 (2%) were 70 years or older.
Main Outcome Measure Comparison of disease-free survival, overall survival, and treatment-related mortality among different age groups.
Results Multivariate analysis showed that smaller tumor size, fewer positive lymph nodes, more chemotherapy, and tamoxifen use were all significantly (P<.001) related to longer disease-free and overall survival. There was no association between age and disease-free survival. Overall survival was significantly (P<.001) worse for patients aged 65 or older because of death from causes other than breast cancer. Thirty-three deaths (0.5% of all patients) were attributed to treatment, and older women had higher treatment-related mortality. Older women and younger women derived similar reductions in breast cancer mortality and recurrence from regimens containing more chemotherapy.
Conclusion Age alone should not be a contraindication to the use of optimal chemotherapy regimens in older women who are in good general health.
